Avtal | $24,000,000 | (Mar 20, 2026)
Parallel(FRANCE) | $20,000,000 | (Mar 20, 2026)
Claros | $30,000,000 | (Mar 20, 2026)
Hemab Therapeutics
Denmark
- Copenhagen, Capital Region
- 22/02/2023
- Series B
- $135,000,000
Hemab Therapeutics ApS is an emerging biotech company supported by Novo Holdings A/S with the aim of developing novel treatments for rare and underserved bleeding disorders. Based in Copenhagen, the company is led by a team of drug developers and scientists with deep expertise in haemophilia. Hemab has exclusive licences to state-of-the-art antibody technologies from both Novo Nordisk A/S and Genmab A/S.
- Industry Biotechnology Research
- Website https://hemab.com/
- LinkedIn https://www.linkedin.com/company/hemabaps/
Related People
Benny SorensenFounder
United States -
Cambridge, Massachusetts
Experienced patient centric Biotechnology Executive with demonstrated translational research, early- intermediate- and late stage clinical development experience. Strong entrepreneurial profile and successful track record of building lean high-performing R&D organizations. Excellent presentation and discussion skills. Extensive pharma-, biotech- and clinical academic high profile network.
Latent | $80,000,000 | (Mar 20, 2026)
Corridor | $25,000,000 | (Mar 20, 2026)
RunSybil | $40,000,000 | (Mar 20, 2026)
PADO AI | $6,000,000 | (Mar 20, 2026)
Edra | $30,000,000 | (Mar 20, 2026)
Chalkie AI | $4,000,000 | (Mar 20, 2026)
Deeptune | $43,000,000 | (Mar 20, 2026)
SetSale | $2,000,000 | (Mar 19, 2026)
Laminar (YC S24) | $3,000,000 | (Mar 19, 2026)